Maxime Chénard-Poirier
Chercheur associé
Axe Oncologie
Dernières nouvelles
Voir tout
Centre de recherche
Recherche clinique : Un essai clinique pour améliorer le traitement du cancer du pancréas
Centre de recherche
Le Centre de recherche du CHU de Québec sur le point de doubler son volume d’études cliniques précoces
Centre de recherche
Vers les traitements de demain avec la recherche clinique de phases 1 et 2 en hémato-oncologie
Publications
-
article Chénard-Poirier M, Hansen AR, Gutierrez ME, Rasco D, Xing Y, Chen LC, Zhou H, Webber AL, Freshwater T, Sharma MR
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Invest New Drugs 42 (3), 2024.
-
article Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, Dragoni I, Heinzmann K, Potter S, Salisbury BM, Chénard-Poirier M, Greystoke A, Howell EC, Innes WA, Morris K, Plummer C, Rata M, Petrides G, Keun HC, Banerji U, Plummer R
A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer
Clin Cancer Res 29 (8), 2023.
-
article Papadatos-Pastos D, Yuan W, Pal A, Crespo M, Ferreira A, Gurel B, Prout T, Ameratunga M, Chénard-Poirier M, Curcean A, Bertan C, Baker C, Miranda S, Masrour N, Chen W, Pereira R, Figueiredo I, Morilla R, Jenkins B, Zachariou A, Riisnaes R, Parmar M, Turner A, Carreira S, Yap C, Brown R, Tunariu N, Banerji U, Lopez J, de Bono J, Minchom A
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
J Immunother Cancer 10 (6), 2022.
Projets
- Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly diagnosed metastatic pancreatic adenocarcinoma: a feasibility and proof-of-concept study, du 2019-10-01 au 2025-03-31
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01), du 2024-05-28 au 2029-12-25